KRAS and pancreatic neoplasm: To address these challenges, DC vaccines targeting KRAS-mutated pancreatic tumors have been developed [102,103], and DC-based immunotherapy has been shown to induce T cell responses against pancreatic cancer antigens, offering the potential to prevent disease recurrence [104].